ProPhase Labs, Inc. Fair Value Adjustment of Warrants
ProPhase Labs, Inc. (PRPH) reported Fair Value Adjustment of Warrants of $225.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-19
- ProPhase Labs, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was $0.00.
- ProPhase Labs, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $185.00K.
- ProPhase Labs, Inc. fair value adjustment of warrants for the quarter ending 2025-06-30 was $40.00K.
- ProPhase Labs, Inc. fair value adjustment of warrants for the quarter ending 2024-12-31 was $0.00.
- ProPhase Labs, Inc. fair value adjustment of warrants for fiscal 2025 was $225.00K.
- ProPhase Labs, Inc. fair value adjustment of warrants for fiscal 2024 was $0.00.
| Period end | Fair Value Adjustment of Warrants 0 month | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $185.00K derived: sum of 2 quarters · filed 2026-06-01 | $225.00K derived: sum of 3 quarters · filed 2026-08-19 | $225.00K 10-K · filed 2026-06-01 | |
| 2025-09-30 | $185.00K 10-Q · filed 2025-11-19 | $225.00K derived: sum of 2 quarters · filed 2026-08-19 | $225.00K 10-Q · filed 2025-11-19 | ||
| 2025-06-30 | $40.00K 10-Q · filed 2026-08-19 | $40.00K 10-Q · filed 2026-08-19 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $0.00 derived: sum of 2 quarters · filed 2026-06-01 | $0.00 derived: sum of 3 quarters · filed 2026-06-01 | $0.00 10-K · filed 2026-06-01 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-19 | $0.00 derived: sum of 2 quarters · filed 2025-11-19 | $0.00 10-Q · filed 2025-11-19 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | |||
| 2015-12-11 | $14.00K 10-Q/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |